Ng. Huilgol et al., AN OVERVIEW OF THE INITIAL EXPERIENCE WITH AK-2123 AS A HYPOXIC CELL SENSITIZER WITH RADIATION IN THE TREATMENT OF ADVANCED HEAD AND NECK CANCERS, International journal of radiation oncology, biology, physics, 34(5), 1996, pp. 1121-1124
Citations number
7
Categorie Soggetti
Oncology,"Radiology,Nuclear Medicine & Medical Imaging
Purpose: AK-2123 (Senazole) is a nitrotriazole with a reported potenti
al for hypoxic cell sensitization. The present study was conducted to
evaluate hypoxic cell potentiation in patients with advanced head and
neck cancer treated with discontinuous accelerated hyperfractionated r
adiation. Methods and Materials: Histologically proven unresectable or
e-pharyngeal cancers Stage T3-4, N0-3, and M0 were randomly allocated
to receive discontinuous accelerated hyperfractionated radiation alone
or with AK-2123. AK-2123 (880 and 990 mg) was administered as an i.v.
infusion between the first and the second fraction of radiation for 1
0 days in two groups of patients. Initial response as a surrogate end
point has been analyzed for comparison and documented for follow-up st
atus. Results: A 100% complete response was observed in both the AK-21
23-treated groups (880 mg and 990 mg), chile, a 44.4% complete respons
e was observed in the control group. There were no treatment-related d
eaths. Neurotoxicity was not reported. Conclusion: Ak-2123 (Senazole)
when administered with discontinuous accelerated hyperfractionated rad
iation showed significant potentiation that, therefore, requires furth
er evaluation.